The global GMP biologics market is on track for strong expansion over the next several years, according to a new forecast highlighted by Persistence Market Research. The market is expected to be worth about US$52.7 billion in 2026 and rise to roughly US$98.2 billion by 2033.
That outlook reflects a projected compound annual growth rate of 9.3% during the forecast period. The report points to continued momentum in the sector as biopharmaceutical innovation supports higher demand for compliant biologics manufacturing and production capacity.
The latest GMP biologics market forecast suggests that companies across the biologics value chain are operating in a favorable growth environment. As new biologic therapies and advanced biopharmaceutical products move forward, the need for manufacturing that meets strict GMP standards is helping lift the market’s long-term prospects.
With the market expected to nearly double in value between 2026 and 2033, the report underscores how important GMP biologics has become within the wider biopharma industry. The combination of innovation, scaling needs and sustained investment is shaping a market that remains a major area of focus for manufacturers and industry stakeholders.
